Terms: = Ovarian cancer AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Treatment
5853 results:
1. Effects of Resveratrol on In Vivo ovarian cancer Cells Implanted on the Chorioallantoic Membrane (CAM) of a Chicken Embryo Model.
Chitcholtan K; Singh M; Tino A; Garrill A; Sykes P
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673959
[TBL] [Abstract] [Full Text] [Related]
2. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
3. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
4. Construction and analysis of competitive endogenous RNA networks and prognostic models associated with ovarian cancer based on the exoRBase database.
Chen Z; Wang C; Ding J; Yu T; Li N; Ye C
PLoS One; 2024; 19(4):e0291149. PubMed ID: 38603733
[TBL] [Abstract] [Full Text] [Related]
5. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
6. Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
Martincuks A; Zhang C; Austria T; Li YJ; Huang R; Lugo Santiago N; Kohut A; Zhao Q; Borrero RM; Shen B; Cristea M; Wang EW; Song M; Rodriguez-Rodriguez L; Yu H
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580335
[TBL] [Abstract] [Full Text] [Related]
7. Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth.
Wilkinson AN; Chen R; Coleborn E; Neilson T; Le K; Bhavsar C; Wang Y; Atluri S; Irgam G; Wong K; Yang D; Steptoe R; Wu SY
Cancer Immunol Immunother; 2024 Mar; 73(5):80. PubMed ID: 38554167
[TBL] [Abstract] [Full Text] [Related]
8. Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes.
Fang CH; Cheng WF; Cheng YF; Lan KL; Lee JM
BMC Cancer; 2024 Mar; 24(1):395. PubMed ID: 38549061
[TBL] [Abstract] [Full Text] [Related]
9. Rosmarinic Acid-Rich
Netala VR; Hou T; Sana SS; Li H; Zhang Z
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542889
[TBL] [Abstract] [Full Text] [Related]
10. CDCA5 promoted cell invasion and migration by activating TGF-β1 pathway in human ovarian cancer cells.
Zhang Q; Zhang R; Li Y; Yang X
J Ovarian Res; 2024 Mar; 17(1):68. PubMed ID: 38539247
[TBL] [Abstract] [Full Text] [Related]
11. FSH induces EMT in ovarian cancer via ALKBH5-regulated Snail m6A demethylation.
Xu X; Zhuang X; Yu H; Li P; Li X; Lin H; Teoh JP; Chen Y; Yang Y; Cheng Y; Chen W; Fu X
Theranostics; 2024; 14(5):2151-2166. PubMed ID: 38505602
[No Abstract] [Full Text] [Related]
12. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
13. The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer.
Hagi T; Vangveravong S; Takchi R; Gong Q; Goedegebuure SP; Tiriac H; Van Tine BA; Powell MA; Hawkins WG; Spitzer D
Sci Rep; 2024 Mar; 14(1):6373. PubMed ID: 38493257
[TBL] [Abstract] [Full Text] [Related]
14. A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers.
Kenney RT; Cini JK; Dexter S; DaFonseca M; Bingham J; Kuan I; Chawla SP; Polasek TM; Lickliter J; Ryan PJ
Front Immunol; 2024; 15():1362775. PubMed ID: 38487528
[TBL] [Abstract] [Full Text] [Related]
15. Biodegradable Local Chemotherapy Platform with Prolonged and Controlled Release of Doxorubicin for the Prevention of Local Tumor Recurrence.
Voznyuk AA; Makarets YA; Advakhova DY; Khafizov KA; Lugovoi ME; Zakharova VA; Senatov FS; Koudan EV
ACS Appl Bio Mater; 2024 Apr; 7(4):2472-2487. PubMed ID: 38480461
[TBL] [Abstract] [Full Text] [Related]
16. Survival and hormone production of isolated mouse follicles in three-dimensional artificial scaffolds after stimulation with bpV(HOpic).
Keckstein P; Dittrich R; Bleisinger N; Hoffmann I; Beckmann MW; Gebhardt A; Schmid B; Keckstein S
Arch Gynecol Obstet; 2024 May; 309(5):2127-2136. PubMed ID: 38472502
[TBL] [Abstract] [Full Text] [Related]
17. Development of an Automatic Rule-Based Algorithm for the Detection of ovarian cancer Recurrence From Electronic Health Records.
Lee S; Kim JH; Ha HI; Lim MC; Cho H
JCO Clin Cancer Inform; 2024 Mar; 8():e2300150. PubMed ID: 38442323
[TBL] [Abstract] [Full Text] [Related]
18. RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter.
Wu H; Xia L; Sun L; Li D; Liu X; Song H; Sheng J; Wang K; Feng Q
J Cell Mol Med; 2024 Mar; 28(6):e18115. PubMed ID: 38436544
[TBL] [Abstract] [Full Text] [Related]
19. Identification and Analysis of Gene Biomarkers for ovarian cancer.
Wang X; Xie C; Lu C
Genet Test Mol Biomarkers; 2024 Feb; 28(2):70-81. PubMed ID: 38416665
[No Abstract] [Full Text] [Related]
20. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract] [Full Text] [Related]
[Next]
